| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Eikon Therapeutics Reports Third Quarter 2026 Financial Results |
| 26 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress |
| 23 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress |
| 14 Aug 2026 |
8-K: Regulation FD Disclosure
Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking stat... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Eikon Therapeutics Reports Second Quarter 2026 Financial Results |
| 03 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective July 31, 2026, Leon Chen, Ph.D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. (the “Company”). Dr. Chen’s and Mr. Wolfe’s resignations were not because of a disagreement with the Company on a... |
| 10 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 5, 2026, the Board of Directors (the “Board”) of Eikon Therapeutics, Inc. (the “Company”) appointed Ma. Fatima D. Francisco to the Board as a Class I director, effective June 15, 2026. Ms. Francisco has been appointed to serve un... |
| 01 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates |
| 30 Mar 2026 |
8-K: Results of Operations and Financial Condition
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates |
| 06 Feb 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Eikon Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), |
Loading...